

Collaborative project “Validation of small molecules for the inhibition of the ion channel TRPM4 to treat neurodegeneration in multiple sclerosis – TRPM4-VIP” funded by the Federal Ministry of Education and Research (BMBF) in Germany

Coordinators: Dr. Philipp Gribbon, Fraunhofer IME and Prof. Dr. Manuel Friese, ZMNH Institute of Neuroimmunology and Multiple Sclerosis (INIMS), UKE

Projects and principal investigators

Second funding period: 06/2020– 05/2022

[Target validation: improving neuronal resilience in multiple sclerosis](#)

Prof. Dr. Manuel Friese, ZMNH Institute of Neuroimmunology and Multiple Sclerosis (INIMS), UKE

Dr. Philip Gribbon, Fraunhofer IME Screening Port

First funding period: 01/2017 – 03/2020

[Target validation: development of pharmacodynamic biomarkers and functional characterization of leading substances for validation](#)

Prof. Dr. Manuel Friese, ZMNH Institute of Neuroimmunology and Multiple Sclerosis (INIMS), UKE and Dr. Philip Gribbon, Fraunhofer IME Screening PortE